2. Search Result
Search Result
Results for "

cyclic peptides

" in MedChemExpress (MCE) Product Catalog:

442

Inhibitors & Agonists

4

Screening Libraries

5

Biochemical Assay Reagents

434

Peptides

84

Natural
Products

9

Isotope-Labeled Compounds

5

Click Chemistry

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0027
    Jasplakinolide
    5+ Cited Publications

    		 Arp2/3 Complex Fungal Infection Cancer
    Jasplakinolide is a potent actin polymerization inducer and stabilizes pre-existing actin filaments. Jasplakinolide binds to F-actin competitively with phalloidin with a Kd of 15 nM. Jasplakinolide, a naturally occurring cyclic peptide from the marine sponge, has both fungicidal and anti-cancer activity .
    Jasplakinolide
  • HY-P0122
    iRGD peptide
    5+ Cited Publications

    c(CRGDKGPDC)

    		 Integrin Cancer
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
    iRGD peptide
  • HY-106783
    Polymyxin B nonapeptide
    2 Publications Verification

    		 Bacterial Antibiotic Infection
    Polymyxin B nonapeptide is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes .
    Polymyxin B nonapeptide
  • HY-P2322
    Iturin A
    1 Publications Verification

    		 Fungal Reactive Oxygen Species (ROS) Apoptosis Autophagy Infection Cancer
    Iturin A is a cyclic lipid peptide with strong antifungal activity. Iturin A induces ROS explosion and induces apoptosis and autophagy in tumor cells. Iturin A has antitumor activity .
    Iturin A
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    2 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-125586
    β-Amanitin

    		DNA/RNA Synthesis ADC Payload Cancer
    β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
    β-Amanitin
  • HY-P1036
    Compstatin
    3 Publications Verification

    		 Complement System Others
    Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .
    Compstatin
  • HY-P10033
    SFTI-1

    		Ser/Thr Protease Others
    SFTI-1 is a cyclic peptide trypsin inhibitor consisting of 14 amino acid residues. SFTI-1 belongs to the Bowman-Birk class of inhibitors. Characterized by its small size, high stability, and potent activity, SFTI-1 can be used for research on peptide drug design platforms .
    SFTI-1
  • HY-N1476
    Heterophyllin B
    4 Publications Verification

    		 PI3K Cancer
    Heterophyllin B is an active cyclic peptide isolated from Pseudostellaria heterophylla. Heterophyllin B provides a novel strategy for the treatment of esophageal cancer .
    Heterophyllin B
  • HY-P3448
    Certepetide

    CEND-1; iRGD; LSTA1

    		 Integrin Complement System Cancer
    Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
    Certepetide
  • HY-P10486
    AIP-II

    		Bacterial Infection
    AIP-II is a cyclic peptide signaling molecule for quorum sensing, which is produced by Staphylococcus aureus. AIP-II potently inhibits AgrC-III in Methicillin (HY-121544)-resistant type III Staphylococcus aureus strain AH1747, with an IC50 of 0.532 nM. AIP-II binds to the AgrC-II receptor and regulates virulence gene expression in Staphylococcus aureus .
    AIP-II
  • HY-P2168
    Demoxytocin

    		Oxytocin Receptor Drug Derivative Metabolic Disease
    Demoxytocin is a heterologous cyclic peptide and an analog of Oxytocin (HY-17571). Demoxytocin affects the permeability of cell membranes and increases calcium ion levels in smooth muscle cells, thereby enhancing the contraction of smooth muscle cells. Demoxytocin also stimulates the contraction of uterine smooth muscle. Demoxytocin possesses the functions of oxytocin. Demoxytocin can be used to study labor stimulation in preterm premature rupture of membranes .
    Demoxytocin
  • HY-129077
    FR179642

    		Drug Intermediate Infection
    FR179642 is a key intermediate in the synthesis of the echinocandin antifungal Micafungin . FR179642 is the cyclic peptide nucleus of the echinocandin-like antifungal lipopeptide FR901379 .
    FR179642
  • HY-P2526
    LyP-1
    2 Publications Verification

    		 Complement System Cancer
    LyP-1 is a cyclic 9-amino-acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells .
    LyP-1
  • HY-P1420
    TAT-cyclo-CLLFVY
    2 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM .
    TAT-cyclo-CLLFVY
  • HY-P1674A
    Murepavadin TFA
    3 Publications Verification

    POL7080 TFA

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
    Murepavadin TFA
  • HY-P10697A
    VH4127 TFA

    		LDLR Metabolic Disease
    VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
    VH4127 TFA
  • HY-146127A
    Grb2 SH2 domain inhibitor 1 TFA

    		Src Others
    Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
    Grb2 SH2 domain inhibitor 1 TFA
  • HY-106783A
    Polymyxin B nonapeptide TFA
    2 Publications Verification

    		 Bacterial Antibiotic Infection
    Polymyxin B nonapeptide TFA is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide TFA is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes .
    Polymyxin B nonapeptide TFA
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)

    c(RGDfE)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-P2300A
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
    2 Publications Verification

    Cyclo(RGDfC) TFA

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
  • HY-P4111
    Peptide R

    		CXCR Inflammation/Immunology Cancer
    Peptide R is a cyclic peptide and a specific CXCR4 antagonist. Peptide R exhibits excellent ability to effectively remodel tumor stroma. Peptide R has potential for use in tumor research .
    Peptide R
  • HY-W012908
    DL-Proline

    		Biochemical Assay Reagents Infection Cancer
    DL-Proline is a racemic mixture of D-Proline and L-Prolin. DL-Proline is a cyclic imino acid with a five-membered ring structure. DL-Proline is a key structural unit in peptide synthesis. DL-Proline can stabilize the β-turn conformation and affect the secondary structure of the peptide. DL-Proline has biological activities such as regulating peptide conformation and enhancing the stability of cyclic peptides. DL-Proline can be used to study diseases related to peptide structure and function, such as cancer and bacterial infection .
    DL-Proline
  • HY-P5957
    Omphalotin A

    		Parasite Infection
    Omphalotin A is a cyclic peptide, and shows nematicidal activity .
    Omphalotin A
  • HY-P10557
    DAG peptide

    		Biochemical Assay Reagents Neurological Disease
    DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .
    DAG peptide
  • HY-P1674
    Murepavadin

    POL7080

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC50 and MIC90 values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
    Murepavadin
  • HY-P1949A
    Cyclic MKEY TFA

    		CXCR Cardiovascular Disease Cancer
    Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .
    Cyclic MKEY TFA
  • HY-P1036A
    Compstatin TFA
    3 Publications Verification

    		 Complement System Others
    Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .
    Compstatin TFA
  • HY-146127
    Grb2 SH2 domain inhibitor 1

    		MEK Cancer
    Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC50 of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2 SH2 domain inhibitor 1 can be used in the research of breast cancer .
    Grb2 SH2 domain inhibitor 1
  • HY-125053A
    Batifiban TFA

    		Glycoprotein VI Cardiovascular Disease
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
    Batifiban TFA
  • HY-P2206
    Zelkovamycin

    		Bacterial Antibiotic Infection
    Zelkovamycin is a cyclic peptide antibiotic originally isolated from Streptomyces. It inhibits growth of X. oryzae, P. oryzae, S. aureus, and A. laidlawii in a concentration-dependent manner when used at concentrations ranging from 0.01 to 300 μg/mL.
    Zelkovamycin
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P2612A
    WP9QY TFA

    		TNF Receptor Others Cancer
    WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)
    WP9QY TFA
  • HY-P0178A
    LXW7 TFA

    		Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7 TFA
  • HY-113469R
    Cyclic GMP (Standard)

    		Endogenous Metabolite Reference Standards Infection Cardiovascular Disease Inflammation/Immunology
    Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .
    Cyclic GMP (Standard)
  • HY-N10583
    Motuporin

    		Others Others
    Motuporin is a cyclic peptide. Motuporin was initially isolated from T. swinhoei .
    Motuporin
  • HY-P11224
    RMI-L4

    		DNA/RNA Synthesis Cancer
    RMI-L4 is an efficient cyclic peptide inhibitor that can specifically disrupt the interaction between FANCM and RMI proteins with an IC50 of 54 nM. RMI-L4 engages the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2.5 nM). RMI-L4 cannot penetrate the cell membrane and can be used to study the FANCM-RMI pathway targeting cancer with alternate lengthening of telomeres (ALT) .
    RMI-L4
  • HY-P1789A
    CTTHWGFTLC, CYCLIC TFA

    		MMP Inflammation/Immunology Cancer
    CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM .
    CTTHWGFTLC, CYCLIC TFA
  • HY-P3193A
    Cyclic nona-L-arginine hydrochloride

    		Biochemical Assay Reagents Others
    Cyclic nona-L-arginine hydrochloride, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts .
    Cyclic nona-L-arginine hydrochloride
  • HY-P10644
    CPP9

    		Fluorescent Dye Cancer
    CPP9 is a small, amphipathic, cyclic cell penetrating peptide (CPP). CPPs bind directly to the plasma membrane phospholipids and enter mammalian cells via endocytosis, followed by efficient release from the endosome. CPP9 can be used for intracellular delivery of therapeutic agents and chemical probes .
    CPP9
  • HY-P10383
    SPSB2-iNOS inhibitory cyclic peptide-1

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
    SPSB2-iNOS inhibitory cyclic peptide-1
  • HY-P4520
    (Trp4)-Kemptide

    		Amino Acid Derivatives Others
    (Trp4)-Kemptide is a peptide substrate for adenosine 3',5'-cyclic monophosphate-dependent protein kinase .
    (Trp4)-Kemptide
  • HY-P3957
    Urotensin II, teleost fish

    		Urotensin Receptor Others
    Urotensin II, teleost fish is a cyclic peptide. It can be isolated from the caudal neurosecretory system of teleost fish .
    Urotensin II, teleost fish
  • HY-134482
    PCSK9-IN-1

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-1 is a novel and highly potent cyclic peptide PCSK9 inhibitor with a Ki value of 1.46 nM.
    PCSK9-IN-1
  • HY-P10697
    VH4127

    		LDLR Metabolic Disease
    VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
    VH4127
  • HY-35028
    Boc-Glu-Ofm

    		Amino Acid Derivatives Others
    Boc-Glu-Ofm is a peptide. Boc-Glu-Ofm has been used for the synthesis of ester insulin and cyclic peptide mixtures .
    Boc-Glu-Ofm
  • HY-P1045
    187-1, N-WASP inhibitor
    1 Publications Verification

    		 Arp2/3 Complex Others
    187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein .
    187-1, N-WASP inhibitor
  • HY-P11038
    IL-23 cyclic peptide inhibitor 105

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 105
  • HY-P11039
    IL-23 cyclic peptide inhibitor 281

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 281
  • HY-W701082
    Cyclo(leucylleucine)

    		Amino Acid Derivatives Others
    Cyclo(leucylleucine) is a cyclic dipeptide formed by the cyclization of two leucine molecules via peptide bonds, and it can be used in the preparation of nanomaterials .
    Cyclo(leucylleucine)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: